Skip To Main Content
Zachary Brennan on Muck Rack

Zachary Brennan

Verified
Washington, D.C.
As seen in: Endpoints News, MSN, MSN Canada, Wiley Online Library, POLITICO, POLITICO Europe, Science Magazine, Yahoo, Genetic Literacy Project, Genetic Engineering & Biotechnology News, Regulatory Affairs Professionals Society and
Senior Editor, Endpoints News - covering the FDA, Capitol Hill, and biotech/pharma - reach me at zachary@endpointsnews.com, Signal: zacharybrennan.20

Get in touch with Zachary

Contact Zachary, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

FDA extends review of Exelixis' colorectal cancer drug candidate

|
By Zachary Brennan Verified
| Endpoints News Verified
FDA extends review of Exelixis' colorectal cancer drug candidate California-based drug developer Exelixis submitted new safety and efficacy data on its potential treatment of metastatic colorectal cancer (mCRC) to the FDA. The new data … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Open in Who Shared Issue with article?

FDA should follow EMA's lead on drug rejection disclosures, researchers say

|
By Zachary Brennan Verified
| Endpoints News Verified
September 9, 2026 12:51 PM EDT FDA should follow EMA's lead on drug rejection disclosures, researchers say The FDA’s major shift in September 2025 to begin publishing drug rejection letters is still an evolving process. But moving forward, the US agency should … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Open in Who Shared Issue with article?

CBER official overruled review team's rejection of new Replimune melanoma drug

|
By Zachary Brennan Verified
| Endpoints News Verified
CBER official overruled review team's rejection of new Replimune melanoma drug Asha Das, director of the FDA biologics center’s office of clinical evaluation, overruled the agency’s review team in granting an accelerated approval to Replimune’s melanoma … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Open in Who Shared Issue with article?
See all 3,063 licensed articles (3,106 Total)